https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-upcoming-january-investor-conferences-2022-01
https://www.nasdaq.com/press-release/aurinia-announces-positive-topline-results-from-the-aurora-2-continuation-study-of
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-2021-jefferies-london-healthcare-conference
https://www.nasdaq.com/press-release/aurinia-reports-third-quarter-and-nine-months-2021-financial-results-and-company
https://www.nasdaq.com/press-release/aurinia-announces-updated-interim-results-from-the-aurora-2-continuation-study-of
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-release-third-quarter-2021-financial-results-on-november-3
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-five-abstracts-at-asn-kidney-week-2021-and-acr
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-upcoming-september-investor-conferences-2021-09
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-participate-in-h.c.-wainwright-23rd-annual-global
https://www.nasdaq.com/press-release/aurinia-acquires-novel-pipeline-assets-targeting-autoimmune-and-kidney-related
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-btig-virtual-biotech-conference-2021-08-09
https://www.nasdaq.com/press-release/aurinia-reports-second-quarter-and-six-months-2021-financial-results-and-recent
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-release-second-quarter-2021-financial-results-on-august-5
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-announces-delisting-from-the-toronto-stock-exchange-2021-07
https://www.nasdaq.com/press-release/aurinia-awards-%24250000-in-grants-to-support-patient-navigation-programs-2021-06-30
https://www.nasdaq.com/press-release/aurinia-announces-licensing-partner-otsuka-filed-initial-marketing-authorization
https://www.nasdaq.com/press-release/aurinia-announces-addition-of-dr.-brinda-balakrishnan-to-the-board-of-directors-2021
https://www.nasdaq.com/press-release/aurinia-announces-results-of-the-2021-annual-general-meeting-2021-06-07
https://www.nasdaq.com/press-release/aurinia-announces-additional-analysis-of-its-aurora-1-phase-3-study-data-presented-at
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-0
https://www.nasdaq.com/press-release/aurinia-to-present-supportive-aurora-2-continuation-study-interim-analysis
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-2021-05
https://www.nasdaq.com/press-release/aurinia-unveils-patient-navigation-grant-program-to-address-access-barriers-for
https://www.nasdaq.com/press-release/aurinia-announces-publication-of-aurora-1-phase-3-study-results-with-lupkynistm
https://www.nasdaq.com/press-release/aurinia-reports-first-quarter-2021-financial-results-and-recent-operational
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-release-first-quarter-2021-financial-results-on-may-6-2021
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-bloom-burton-co.-healthcare-investor
https://www.nasdaq.com/press-release/aurinia-presents-data-demonstrating-lupkynistm-voclosporin-efficacy-across-lupus
https://www.nasdaq.com/press-release/aurinia-announces-positive-cost-effectiveness-assessment-of-lupkynistm-voclosporin-in
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-three-upcoming-march-investor-conferences-2021
https://www.nasdaq.com/press-release/aurinia-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-svb-leerink-10th-annual-global-healthcare
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-release-fourth-quarter-and-year-end-2020-financial-results
https://www.nasdaq.com/press-release/fda-approves-aurinia-pharmaceuticals-lupkynistm-voclosporin-for-adult-patients-with
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-two-upcoming-virtual-healthcare-conferences
https://www.nasdaq.com/press-release/aurinia-announces-collaboration-and-licensing-agreement-with-otsuka-pharmaceutical-co
https://www.nasdaq.com/press-release/aurinia-and-lonza-announce-exclusive-agreement-for-dedicated-voclosporin
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-piper-sandler-32nd-annual-virtual
https://www.nasdaq.com/press-release/aurinia-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635c4
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-2020-jefferies-virtual-london-healthcare
https://www.nasdaq.com/press-release/aurinia-reports-third-quarter-2020-financial-results-and-recent-operational
https://www.nasdaq.com/press-release/aurinia-presents-integrated-time-to-renal-response-data-from-the-aura-lv-and-aurora
https://www.nasdaq.com/press-release/aurinia-announces-outcome-of-audreytm-clinical-trial-in-dry-eye-syndrome-2020-11-02
https://www.nasdaq.com/press-release/aurinia-announces-european-investigator-initiated-trial-to-evaluate-antiviral
https://www.nasdaq.com/press-release/aurinia-presents-voclosporin-efficacy-and-pharmacokinetic-data-from-integrated
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-announces-launch-of-lupus-nephritis-disease-state-awareness
https://www.nasdaq.com/press-release/aurinia-announces-new-employment-inducement-grants-under-nasdaq-listing-rule-5635c4-0
https://www.nasdaq.com/press-release/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-three-upcoming-virtual-investor-conferences
https://www.nasdaq.com/press-release/aurinia-announces-new-employment-inducement-grants-under-nasdaq-listing-rule-5635c4
https://www.nasdaq.com/press-release/aurinia-reports-second-quarter-2020-financial-results-and-recent-operational
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-btig-virtual-biotechnology-conference-2020
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-report-second-quarter-2020-financial-results-on-august-11
https://www.nasdaq.com/press-release/aurinia-closes-us%24200-million-public-offering-of-common-shares-2020-07-27
https://www.nasdaq.com/press-release/aurinia-prices-us%24200-million-public-offering-of-common-shares-2020-07-22
https://www.nasdaq.com/press-release/aurinia-announces-public-offering-of-common-shares-2020-07-22
https://www.nasdaq.com/press-release/aurinia-announces-u.s.-food-and-drug-administration-acceptance-of-the-filing-of-new
https://www.nasdaq.com/press-release/aurinia-completes-patient-enrollment-into-the-audrey-phase-2-3-clinical-trial-of
https://www.nasdaq.com/press-release/aurinia-presents-additional-aurora-pivotal-trial-safety-data-at-the-era-edta-virtual
https://www.nasdaq.com/press-release/aurinia-presents-aurora-pivotal-trial-subgroup-analysis-at-the-eular-2020-e-congress
https://www.nasdaq.com/press-release/aurinia-announces-results-of-annual-general-meeting-2020-06-03
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference
https://www.nasdaq.com/press-release/aurinia-completes-submission-of-new-drug-application-to-the-u.s.-food-drug
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-2020-rbc-capital-markets-virtual-global
https://www.nasdaq.com/press-release/aurinia-reports-first-quarter-2020-financial-results-and-recent-operational
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-release-first-quarter-2020-financial-results-on-may-14
https://www.nasdaq.com/press-release/aurinia-appoints-joe-miller-as-chief-financial-officer-2020-04-27
https://www.nasdaq.com/press-release/aurinia-appoints-industry-veteran-timothy-p.-walbert-to-its-board-of-directors-2020
https://www.nasdaq.com/press-release/aurinia-announces-aurora-phase-3-clinical-data-for-voclosporin-in-lupus-nephritis-to
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-establishes-u.s.-commercial-operations-center-in-rockville
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-initiates-rolling-submission-of-a-new-drug-application-to-the
https://www.nasdaq.com/press-release/aurinia-launches-resource-kit-for-people-living-with-lupus-nephritis-and-partners
https://www.nasdaq.com/press-release/aurinia-reports-fourth-quarter-and-full-year-2019-financial-results-and-operational
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-release-fourth-quarter-and-full-year-2019-financial
https://www.nasdaq.com/press-release/aurinia-appoints-max-colao-as-chief-commercial-officer-and-expands-u.s.-commercial
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-9th-annual-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/aurinia-closes-us%24191.7-million-public-offering-of-common-shares-and-full-exercise-of
https://www.nasdaq.com/press-release/aurinia-prices-us%24166.7-million-public-offering-of-common-shares-2019-12-09
https://www.nasdaq.com/press-release/aurinia-announces-public-offering-of-common-shares-2019-12-09
https://www.nasdaq.com/press-release/aurinia-announces-positive-aurora-phase-3-trial-results-demonstrating-voclosporin
https://www.nasdaq.com/press-release/aurinia-to-present-preclinical-voclosporin-data-at-2020-keystone-symposia-conference
https://www.nasdaq.com/press-release/aurinia-reports-third-quarter-2019-financial-results-and-recent-operational
https://www.nasdaq.com/press-release/aurinia-announces-updates-to-the-board-of-directors-2019-11-13
https://www.nasdaq.com/press-release/aurinia-completes-voclosporin-drug-drug-interaction-study-demonstrating-no-clinically
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-release-third-quarter-2019-financial-results-on-november
https://www.nasdaq.com/press-release/aurinia-announces-initiation-of-patient-dosing-in-phase-2-3-audreytm-clinical-trial
https://www.nasdaq.com/press-release/aurinia-reports-last-patient-study-visit-in-aurora-phase-3-lupus-nephritis-study-and
https://www.nasdaq.com/press-release/aurinia-pharmaceuticals-to-present-at-the-2019-cantor-global-healthcare-conference
